Navigation Links
Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
Date:10/12/2011

CRANBURY, N.J., Oct. 12, 2011 /PRNewswire/ -- Oncobiologics, Inc. announced today that is has named Scott Canute, a former President at both Eli Lilly and Genzyme, to its Board of Directors.  

Over the course of his 30-year career, Mr. Canute played a vital role in leading Eli Lilly's global manufacturing operations.  Most recently, he spent more than a year as President of Global Manufacturing and Corporate Operations for Genzyme, where he led a major turnaround effort.

"Scott Canute has been a distinguished leader at major biopharmaceutical organizations throughout his career," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D.  "I have known and admired Scott as my mentor for many years, and I am honored that he will share his experience and strategic insight to our efforts at Oncobiologics.  We look forward to guidance from Scott as a member of our board."

"Oncobiologics has assembled an impressive team of industry leaders, and already has developed a promising pipeline," said Mr. Canute.  "Although the company is a start-up, it has the horsepower of a much more established organization.  I look forward to helping Pankaj steer the company through this exciting stage."

Mr. Canute earned a Master of Business Administration from the Harvard Business School.  He also earned a B.S. in Chemical Engineering at the University of Michigan, where he graduated with Highest Honors.

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Omeros Appoints David A. Mann to its Board of Directors
4. RainDance Technologies Appoints Olex Vice President, System Development
5. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
6. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
7. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
8. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
9. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
10. UltraShape Appoints Assaf Eyal as President & CEO
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):